Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Oncopeptides AB ( (SE:ONCO) ) has shared an update.
Oncopeptides has reported Phase 2 BRIDGE study results showing that its cancer drug Pepaxti, combined with dexamethasone, can be safely and effectively used in relapsed, refractory multiple myeloma patients with moderate-to-severe renal impairment, a group that represents about half of all myeloma cases and typically has poorer outcomes. The peer-reviewed data demonstrate that a reduced 30 mg starting dose in patients with moderate renal impairment maintains a manageable safety profile, robust response rates, and stable or slightly improved kidney function, thereby supporting wider clinical use of Pepaxti in fragile patient populations and strengthening the company’s scientific position in this indication.
More about Oncopeptides AB
Oncopeptides AB is a Swedish biotech company specializing in targeted therapies for difficult-to-treat cancers, leveraging its proprietary Peptide Drug Conjugate and SPiKE platforms to deliver cytotoxic agents directly into cancer cells. Its flagship drug Pepaxti is being commercialized in Europe, supported by partnership agreements in South Korea, the Middle East, Africa and other regions, with operations across several European countries and a listing on Nasdaq Stockholm.
Average Trading Volume: 4,737,545
Technical Sentiment Signal: Sell
Current Market Cap: SEK664M
For detailed information about ONCO stock, go to TipRanks’ Stock Analysis page.